All In Biotech

Drug Trial Radar · NCT04740931

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

Last checked: Nov 20, 2026Latest source record: Aug 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 729 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

729

Actual

Start

Mar 2, 2021

Primary completion

Aug 9, 2022

Study completion Jul 12, 2023

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Chugai Pharmaceutical
First posted
Feb 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals until Week 24, followed by a double-masked period of study without active control to evaluate faricimab administered according to a personalized treatment interval (PTI) dosing regimen in patients with macular edema due to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO).

Conditions

  • Macular Edema
  • Central Retinal Vein Occlusion
  • Hemiretinal Vein Occlusion

Interventions

  • FaricimabDrug

    Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.

  • AfliberceptDrug

    Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).

  • Sham ProcedureProcedure

    The sham is a procedure that mimics an IVT injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24Time frame: From Baseline through Week 24

Locations

194 sites in 22 countries. Site status is shown where the registry gives one.

  • Barnet Dulaney Perkins Eye Center

    Mesa, Arizona

  • Retinal Research Institute, LLC

    Phoenix, Arizona

  • Retina Associates Southwest PC

    Tucson, Arizona

  • Retinal Diagnostic Center

    Campbell, California

  • The Retina Partners

    Encino, California

  • Retina Consultants of Orange County

    Fullerton, California

  • Northern California Retina Vitreous Associates

    Mountain View, California

  • East Bay Retina Consultants

    Oakland, California

  • California Eye Specialists Medical group Inc.

    Pasadena, California

  • Retina Consultants, San Diego

    Poway, California

  • West Coast Retina Medical Group

    San Francisco, California

  • Retina Consultants of Southern Colorado PC

    Colorado Springs, Colorado

  • Colorado Retina Associates, PC

    Lakewood, Colorado

  • Retina Group of New England

    Waterford, Connecticut

  • Advanced Research

    Deerfield Beach, Florida

  • Rand Eye

    Deerfield Beach, Florida

  • Florida Eye Associates

    Melbourne, Florida

  • Fort Lauderdale Eye Institute

    Plantation, Florida

  • Retina Vitreous Assoc of FL

    St. Petersburg, Florida

  • Retina Associates of Florida, LLC

    Tampa, Florida

  • Southeast Retina Center

    Augusta, Georgia

  • Georgia Retina PC

    Marietta, Georgia

  • Retina Consultants of Hawaii

    ‘Aiea, Hawaii

  • Northwestern Medical Group/Northwestern University

    Chicago, Illinois

  • Retina Associated Ltd

    Elmhurst, Illinois

  • University Retina and Macula Associates, PC

    Oak Forest, Illinois

  • Prairie Retina Center

    Springfield, Illinois

  • Retina Associates

    Lenexa, Kansas

  • Johns Hopkins Med; Wilmer Eye Inst

    Baltimore, Maryland

  • Retina Group of Washington

    Chevy Chase, Maryland

  • Cumberland Valley Retina PC

    Hagerstown, Maryland

  • Assoc Retinal Consultants PC

    Royal Oak, Michigan

  • VitreoRetinal Surgery, PLLC.; DBA Retina Consultants of Minnesota

    Edina, Minnesota

  • Midwest Vision Research Foundation

    Chesterfield, Missouri

  • Sierra Eye Associates

    Reno, Nevada

  • Long Is. Vitreoretinal Consult

    Hauppauge, New York

  • Retina Vit Surgeons/Central NY

    Liverpool, New York

  • Retina Assoc of Western NY

    Rochester, New York

  • Cincinnati Eye Institute

    Cincinnati, Ohio

  • Retina Northwest

    Portland, Oregon

Showing 40 of 194 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.